MA27679A1 - Derives d'acides carboxyliques en tant qu'antagonistes ip - Google Patents

Derives d'acides carboxyliques en tant qu'antagonistes ip

Info

Publication number
MA27679A1
MA27679A1 MA26816A MA26816A MA27679A1 MA 27679 A1 MA27679 A1 MA 27679A1 MA 26816 A MA26816 A MA 26816A MA 26816 A MA26816 A MA 26816A MA 27679 A1 MA27679 A1 MA 27679A1
Authority
MA
Morocco
Prior art keywords
antagonists
carboxylic acid
acid derivatives
derivatives
carboxylic
Prior art date
Application number
MA26816A
Other languages
English (en)
Inventor
Richard Leo Cournoyer
Paul Francis Keitz
Lee Edwin Lowrie Jr
Alexander Victor Muehldorf
Counde O'yang
Dennis Mitsugu Yasuda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA27679A1 publication Critical patent/MA27679A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
MA26816A 2000-03-16 2002-09-12 Derives d'acides carboxyliques en tant qu'antagonistes ip MA27679A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19012900P 2000-03-16 2000-03-16
US24712900P 2000-11-10 2000-11-10

Publications (1)

Publication Number Publication Date
MA27679A1 true MA27679A1 (fr) 2006-01-02

Family

ID=26885804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26816A MA27679A1 (fr) 2000-03-16 2002-09-12 Derives d'acides carboxyliques en tant qu'antagonistes ip

Country Status (21)

Country Link
US (3) US6693098B2 (fr)
EP (1) EP1265853A1 (fr)
JP (1) JP3938689B2 (fr)
KR (1) KR100523119B1 (fr)
CN (1) CN1241909C (fr)
AR (1) AR028252A1 (fr)
AU (2) AU2001252168B2 (fr)
BR (1) BR0109235A (fr)
CA (1) CA2401502C (fr)
CZ (1) CZ20023422A3 (fr)
HR (1) HRP20020733A2 (fr)
HU (1) HUP0300188A3 (fr)
IL (1) IL151478A (fr)
MA (1) MA27679A1 (fr)
MX (1) MXPA02008931A (fr)
NO (1) NO328526B1 (fr)
NZ (1) NZ521028A (fr)
PL (1) PL207869B1 (fr)
RU (1) RU2268258C2 (fr)
WO (1) WO2001068591A1 (fr)
YU (1) YU68102A (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU68102A (sh) * 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti
ATE309994T1 (de) 2001-03-02 2005-12-15 Hoffmann La Roche Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
EP1368345B1 (fr) 2001-03-02 2006-03-22 F. Hoffmann-La Roche AG Derives d'acide alcoxycarbonylaminoheteroaryle carboxylique en tant qu'antagonistes d'ip
CA2475434C (fr) * 2002-02-07 2011-04-05 Hitoshi Endou Derives d'amino-acides aromatiques et compositions medicamenteuses
GB2389580A (en) * 2002-06-12 2003-12-17 Bayer Ag 2-Naphthamide PGI2 antagonists
GB2389582A (en) * 2002-06-13 2003-12-17 Bayer Ag Pharmaceutically active carboxamides
CA2505361A1 (fr) * 2002-11-11 2004-05-27 Bayer Healthcare Ag Derives de phenyl- ou heteroarylamino-alcanes comme antagonistes du recepteur ip
ATE405840T1 (de) 2002-12-19 2008-09-15 Scripps Research Inst Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
EP1594846A1 (fr) * 2003-02-10 2005-11-16 Bayer HealthCare AG Derives de bis(hetero)aryle carboxamide destines a etre utilises en tant qu'antagonistes de la pg12
WO2004071508A1 (fr) * 2003-02-14 2004-08-26 Medical Research Council Antagonistes du recepteur ip utilises dans le traitement des pathologies de l'uterus
DE10332560B4 (de) * 2003-07-11 2010-07-08 Chiracon Gmbh Verfahren zur Herstellung von ß- Heteroaryl-2-alanin-Verbindungen über 2-Amino-2-(heteroarylmethyl)-carbonsäure-Verbindungen
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
JP2007538103A (ja) 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
WO2006029735A1 (fr) * 2004-09-15 2006-03-23 Bayer Healthcare Ag Diagnostic et therapie de maladies associees au recepteur de la prostaglandine i2 (ptgir)
CA2645099A1 (fr) * 2006-03-24 2007-10-04 Wyeth Methodes pour moduler la fonction de la vessie
WO2008034016A2 (fr) * 2006-09-15 2008-03-20 Foldrx Pharmaceuticals, Inc. Dosages pour détecter des protéines à l'état natif et identifier des composés qui modulent la stabilité desdites protéines
TWI449040B (zh) * 2006-10-06 2014-08-11 Crocus Technology Sa 用於提供內容可定址的磁阻式隨機存取記憶體單元之系統及方法
CN110003123B (zh) * 2008-03-18 2023-06-23 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
ATE538474T1 (de) * 2008-04-07 2012-01-15 Crocus Technology Sa System und verfahren zum schreiben von daten auf magnetoresistive direktzugriffsspeicherzellen
EP2124228B1 (fr) * 2008-05-20 2014-03-05 Crocus Technology Mémoire à accès aléatoire magnétique avec une jonction elliptique
US8031519B2 (en) * 2008-06-18 2011-10-04 Crocus Technology S.A. Shared line magnetic random access memory cells
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
RS55856B1 (sr) * 2010-07-14 2017-08-31 Novartis Ag Heterociklična jedinjenja agonisti ip receptora
BR112013004164A2 (pt) * 2010-08-23 2016-05-10 Novartis Ag processo para a preparação de intermediários para a produção de inibidores da nep
RU2586330C2 (ru) 2011-09-16 2016-06-10 Пфайзер Инк. Твердые формы ингибитора диссоциации транстиретина
CN104053659B (zh) * 2012-01-13 2016-11-09 诺华股份有限公司 用于治疗肺动脉高压(pah)及相关病症的作为ip 受体激动剂的稠合的吡咯类
WO2014143592A1 (fr) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition de la néovascularisation par inhibition des récepteurs de prostanoïde ip
WO2014143591A1 (fr) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition de la néovascularisation par inhibition simultanée de prostanoïde ip et des récepteurs ep4
US9732035B2 (en) * 2015-07-24 2017-08-15 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-D-tryptophan
EP3977985B1 (fr) 2017-03-01 2023-09-06 Arena Pharmaceuticals, Inc. Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés
AU2019216531A1 (en) 2018-02-02 2020-09-24 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN111408314B (zh) * 2020-04-17 2021-08-10 甘肃智仑新材料科技有限公司 一种含炔基阳离子表面活性剂及其制备方法
CA3212050A1 (fr) * 2021-03-18 2022-09-22 Weizhen Wang Methodes et compositions de traitement de maladies oculaires
WO2023158634A1 (fr) 2022-02-15 2023-08-24 United Therapeutics Corporation Agoniste du récepteur de prostacycline (ip) cristalline et ses utilisations
US12427124B1 (en) * 2024-04-10 2025-09-30 Maxymune Therapeutics, Inc. Phenylalanine-based LAT1 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895344A (en) 1957-08-30 1962-05-02 Ciba Ltd Method of temporary protection of hydroxy, mercapto and amino groups
DE1793827A1 (de) 1967-01-25 1976-05-13 Ciba Geigy Ag Neue aminoschutzgruppen, ihre verwendung bei peptidsynthesen und verfahren zur herstellung der entsprechend geschuetzten aminosaeuren und peptide
US3875207A (en) 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
DE1934783A1 (de) 1969-07-09 1971-01-28 Bayer Ag Biphenylisopropyloxycarbonylfluorid und seine Verwendung zur Acylierung von Aminosaeuren
DE2641060A1 (de) 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
US4145337A (en) 1977-10-11 1979-03-20 Hoffmann-La Roche Inc. Aminoethylglycine containing polypeptides
PL265549A1 (en) * 1985-03-26 1988-09-01 The method of manufacture of new heterocyclic amides
JPH0672985B2 (ja) 1986-05-29 1994-09-14 株式会社ハツコウ メガネ枠フイツテイング調整システム
NZ221729A (en) 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US5250517A (en) 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
EP1000930A3 (fr) 1992-08-13 2003-10-29 Warner-Lambert Company Antagonistes de tachykinines
JPH0672985A (ja) 1992-08-28 1994-03-15 Ono Pharmaceut Co Ltd （チオ）ウレア誘導体
JP3118738B2 (ja) 1992-12-22 2000-12-18 小野薬品工業株式会社 （チオ）ウレア誘導体
ATE206710T1 (de) 1994-06-06 2001-10-15 Warner Lambert Co Tachykinin (nk1) rezeptor antagonisten
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69707843T2 (de) * 1996-03-20 2002-05-16 Aventis Pharma S.A., Antony TRIZYCLISCHE VERBINDUNGEN MIT WIRKUNG AUF INTEGRINE, BESONDERS AUF DAS ALPHAvBETA3-INTEGRIN, VERFAHREN ZUR IHRER HERSTELLUNG UND ZWISCHENPRODUKTE DES VERFAHRENS, IHRE VERWENDUNG ALS ARZNEIMITTEL UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
NZ331480A (en) * 1997-09-04 2000-02-28 F 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions
YU68102A (sh) 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti

Also Published As

Publication number Publication date
US20010056100A1 (en) 2001-12-27
EP1265853A1 (fr) 2002-12-18
JP2003527368A (ja) 2003-09-16
JP3938689B2 (ja) 2007-06-27
HRP20020733A2 (en) 2005-02-28
CA2401502A1 (fr) 2001-09-20
HK1054924A1 (en) 2003-12-19
CN1241909C (zh) 2006-02-15
AU2001252168B2 (en) 2007-07-12
US20060035870A1 (en) 2006-02-16
US7056903B2 (en) 2006-06-06
CZ20023422A3 (cs) 2003-01-15
NO328526B1 (no) 2010-03-08
YU68102A (sh) 2006-01-16
KR100523119B1 (ko) 2005-10-20
HUP0300188A3 (en) 2004-07-28
NO20024387D0 (no) 2002-09-13
HUP0300188A2 (hu) 2003-06-28
RU2268258C2 (ru) 2006-01-20
PL207869B1 (pl) 2011-02-28
RU2002127781A (ru) 2004-03-20
US20030220367A1 (en) 2003-11-27
AR028252A1 (es) 2003-04-30
BR0109235A (pt) 2002-12-17
NZ521028A (en) 2004-07-30
US7312230B2 (en) 2007-12-25
PL358216A1 (en) 2004-08-09
KR20020091135A (ko) 2002-12-05
US6693098B2 (en) 2004-02-17
CN1418187A (zh) 2003-05-14
CA2401502C (fr) 2010-09-21
WO2001068591A1 (fr) 2001-09-20
MXPA02008931A (es) 2003-02-10
AU5216801A (en) 2001-09-24
IL151478A (en) 2009-07-20
NO20024387L (no) 2002-10-21

Similar Documents

Publication Publication Date Title
NO20024387D0 (no) Karboksylsyrederivater som IP-antagonister
FR15C0086I2 (fr) Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
FR20C1039I2 (fr) Derives de l'uk-2a
MA26958A1 (fr) Derives de 2-phenylaminoimidazoline phenyl cetone substituee en tant qu'antagonistes ip
EP1165541A4 (fr) Composes dimeres en tant qu'inhibiteurs de la neuraminidase
MA26972A1 (fr) Derives du tetralone en tant qu'agents anti-tumeur
DZ3117A1 (fr) Production d'acides carboxyliques aromatiques.
MA27680A1 (fr) Derives de 4-phenyl-pyridine en tant qu'antagonistes du recepteur de la neurokinine-1
FR17C0008I2 (fr) Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2
EP1320366A4 (fr) Piperidines substituees en tant qu'agonistes de recepteurs de la melanocortine
EP1268449A4 (fr) Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
MA26994A1 (fr) Quinazolines en tant qu'inhibiteurs de la mmp-13
EP1773768A4 (fr) Derives de pyrrole en tant qu'agents pharmaceutiques
DZ3246A1 (fr) Dérivé heterocyclo-alkylsulfonyle pyrazole en tant qu'agents anti-inflammatoires/analgesiques
ATE228995T1 (de) Aminomethylcarbonsäurederivate
NO20041235L (no) Kinolinderivater som neuropeptid Y antagonister
EP1295865A4 (fr) Nouveaux derives d'acide dicarboxylique
IL151093A0 (en) Derivatives of quinoline as alpha-2 antagonists
DE50104794D1 (de) Substituierte anthranilsäuren
MA27046A1 (fr) Nouveaux derives d'oxazolidinones en tant qu'agents antibacteriens.
MA27033A1 (fr) Derives d'acides sulfoniques nouveaux
FR2813756B1 (fr) Dilueur pour la conservation de spermatozoides de porcins
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
ATE309994T1 (de) Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten
ATE321041T1 (de) Alkoxycarbonylamino-heteroaryl- carbonsäurederivate als ip-antagonisten